🔗 Share this article

As the US continues making unprecedented adjustments to its vaccine guidelines, a particular individual has emerged unexpectedly: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by casting doubt on Covid vaccines in the global health crisis and has zeroed in on possible deaths following COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Health officials planned to reveal major changes to the childhood immunization program recently, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US out of alignment with a large portion of the international standard with insufficient data for improved outcomes. The announcement has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to lead the division this year.

A New Direction at the Agency

This interim role could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for halting some childhood shot schedules in the US in order to be more in line with Denmark, a nation with universal health coverage and a number of inhabitants roughly the size of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccination policy – typically the purview of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Questions Over Qualifications

The appointee has little discernible experience in drug development, approval processes or administrative roles, which has been customary for former leaders of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She is not an expert in industry regulation.”

Former commissioners of the center would “grasp regulatory frameworks and the science of drug development”, said Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who led CBER have had.”

This division has an vast workload at the FDA, she stated.

“Everybody just zeroes in on the innovative therapies, but the generic program approves numerous generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and all of those have to be looked after,” Woodcock noted. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major management component to the role, which supervises over 5,000 staff members. “It is a massive administrative position, if you execute it properly,” the former official concluded.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Høeg’s fitness for the role and whether this appointment represents more teamwork among agency officials on vaccines, a representative responded that the “questions stem from incorrect presumptions”.

“Her resume is consistent with the functions of her position,” the representative said, noting the period Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious one-day drug-approval program that allegedly worried her former heads. “How are these therapies being picked for this fast-track system? Who is making the choices?” Howard questioned. “There is a lot of secrecy happening at the FDA right now.”

Overall, he said, “the agency seems to be moving towards more relaxed rules of pharmaceuticals, with the exception of shots.”

Established Past Work on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if concerning, history, critics observe. She published a research paper using unverified volunteer-provided data to assess the frequency of heart inflammation following Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to indicate Covid vaccinations are riskier than they are.

Included in her “policy goals” for the incoming government featured changing regulations for recently developed shots and ending “optional” vaccines, she remarked following the vote on a audio program. At the FDA, Dr. Høeg has allegedly suggested barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete ideologue who begins with her conclusions and works backwards to accommodate the science in a extremely disingenuous, untruthful manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg joined fellow skeptics, {like|